OKYO Pharma enrolls first patients in Phase 3 NEPTUNE trial of urcosimod
OKYO Pharma has begun enrolling participants in its Phase 3 NEPTUNE study of urcosimod for neuropathic corneal pain. The initial patients were entered at the Toyos Clinic in Nashville by Dr. Melissa Toyos, and additional sites in the United States and Europe will be added. The protocol calls for four eye‑drop doses each day for 12 weeks and will measure pain reduction with a visual‑analog‑scale score. The company views the trial as a step toward a disease‑modifying therapy for a condition that currently lacks approved treatments.
Why it matters
Material 2 states that a successful trial outcome could support a regulatory filing, which may be viewed positively by investors.
Key facts
- 1OKYO Pharma announced that the first participants have been entered into its Phase 3 NEPTUNE study of urcosimod. globenewswire.com
- 2The initial enrollment was performed at the Toyos Clinic in Nashville, Tennessee by Dr. Melissa Toyos. globenewswire.com
- 3The NEPTUNE trial will run at sites in the United States and also in Italy, Spain and France. globenewswire.com
- 4Each subject will be given four eye‑drop administrations daily for a period of 12 weeks. finance.yahoo.com
- 5The primary efficacy measure is the change in ocular pain visual‑analog‑scale score from baseline to the end of treatment. finance.yahoo.com
- 6Chief Medical Officer Flavio Mantelli said the activation of the first site marks a key milestone for building clinical evidence. globenewswire.com
Summary written by AlphAI from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.